Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes

Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-rearranged malignancies, particularly in non-small-cell lung cancer (NSCLC), which has generated considerable interest and effort in developing ALK tyrosine kinase inhibitors (TKI). Crizotinib was the first ALK inhibitor...

Full description

Saved in:
Bibliographic Details
Published in:Cancers (Basel)
Main Authors: Sharma, Geeta Geeta, Mota, Ines, Mologni, Luca, Patrucco, Enrico, Gambacorti-Passerini, Carlo, Chiarle, Roberto
Format: Artigo
Language:Inglês
Published: MDPI 2018
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5876637/
https://ncbi.nlm.nih.gov/pubmed/29495603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10030062
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items